Annual Report & Accounts 2010 - Board of Directors
Alan Reade -Executi ve Chairman
Alan Reade (Executive Chairman) was appointed on 25 May 2007 as Non-executive Director.
He is the owner of Global Strategy Expression Limited, a consulting and advisory services
business in the life sciences industry. From 2000 until his retirement in 2005, he served as executive
chairman of Merial Limited, a leading animal health company and joint venture between
Merck & Co. Inc. and Sanofi-Aventis. Earlier in his career he was head of global integration at
Aventis, where he was in charge of merger integration, and Chief Executive Officer and member
of the Global Executive Committee at Rhone-Poulenc Inc. He previously has been a director of
Sygen International and IFAH, a global animal health association as well as more than 40 Merial
subsidiaries. He was chairman of the Remuneration Committee until his appointment as executive
Chairman and member of the Nomination Committee
throughout the year. Subsequent to
the year end, on 4 January 2010 he was appointed as Executive Chairman.
James Hills -Non -executi ve Director
James Hills (Non-executive Director) was appointed on 9 July 2010. Mr. Hills spent the early
portion of his career with The Gillette Company and Coca Cola USA where he held senior
positions in both sales and brand management. Later, he became a 50% partner and Chief
Executive Officer of Weatherly Consumer Products Inc. (Jobe's), a company which developed,
branded and marketed specialty fertilizers in North America and Europe. Following the sale of
that business in 1996, he and a partner started Gulfstream Home and Garden, a company that
marketed consumer insecticides for the lawn and garden market in the U.S. Mr. Hills sold
Gulfstream in 2005, following nearly ten years of rapid growth. He is chairman of the Remuneration
Committee and a member of the Audit and Nomination Committees.
Barrington Marshall Riley -Non -executi ve Director
Barry Riley (Non-executive Director) was appointed on 25 May 2007. After qualifying as a
Chartered Accountant, he joined the Bowater Organization, where he had responsibility for the
finance function at several operations. From there he moved to FMC Corporation, the US
conglomerate where he had finance and general management responsibilities for a specialty
chemical operation, and also oversaw the head office finance function for all UK operations.
He joined Proteus International plc in 1995 as Finance Director and was closely involved in the
merger with Therapeutic Antibodies Inc. in 1999, which became Protherics plc where he was
Finance Director until 2007. He is chairman of the Audit Committee and a member of the
Nomination and Remuneration Committee
and is also the Senior Independent Director.
Board of Directors
12
